Minimal hepatic encephalopathy

Area of Science:

• Hepatology
• Neurology
• Gastroenterology

Background:

• Minimal hepatic encephalopathy (MHE) is the earliest stage of hepatic encephalopathy, affecting up to 80% of patients with cirrhosis.
• MHE presents with subclinical neurocognitive deficits in attention, vigilance, and executive function, impacting quality of life, driving ability, and mortality.
• Despite its impact, MHE is often undiagnosed and untreated due to its lack of obvious clinical symptoms.

Purpose of the Study:

• To highlight the clinical significance of MHE in cirrhotic patients.
• To discuss current diagnostic methods for MHE.
• To introduce novel screening tools and treatment options for MHE.

Main Methods:

• Review of existing literature on MHE diagnosis and treatment.
• Introduction of the EncephalApp Stroop Test as a potential smartphone-based screening tool.
• Discussion of pharmacological and non-pharmacological interventions.

Main Results:

• MHE significantly affects patients' daily functioning, quality of life, and survival.
• Traditional diagnostic methods include neuropsychological tests and the critical flicker frequency test.
• A smartphone application (EncephalApp Stroop Test) shows promise as a screening tool for MHE.
• Treatment options include lactulose, probiotics, and rifaximin, though liver transplantation may not fully reverse cognitive deficits.

Conclusions:

• MHE is a clinically relevant condition in cirrhotic patients that warrants diagnosis and management.
• Novel tools like the EncephalApp Stroop Test can aid in early MHE detection.
• While treatments exist, the long-term cognitive impact of MHE, even post-transplant, requires further investigation.